



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1616  
RECEIVED  
MAY 16 2003  
TECHNICAL CENTER 1600/2900  
613  
VCS  
5-21-3

Application of: P. RUBIN

Application No.: 10/084,250

Group Art Unit: 1616

Filed: February 28, 2002

Examiner: M. Haghighatian

For: METHODS AND COMPOSITIONS  
USING NORASTEMIZOLE IN  
COMBINATION WITH LEUKOTRIENE  
INHIBITORS

Attorney Docket No.: 4821-469

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated February 24, 2003, Applicant submits the following remarks for entry into the record and consideration by the Examiner.

IN THE CLAIMS

Please rewrite claims 30-36, 38, and 40 as follows:

31. (Amended) The method of claim <sup>1</sup>12 or <sup>2</sup>13, wherein the amount of norastemizole administered is from about 10 mg to about 100 mg per day.

32. (Amended) The method of claim <sup>1</sup>12 or <sup>2</sup>13, wherein the compositions are administered as a nasal or oral spray.

33. (Amended) The method of claim <sup>1</sup>12 or <sup>2</sup>13, wherein at least one of the norastemizole and the leukotriene inhibitor is administered as a nasal or oral spray.

34. (Amended) The method of claim <sup>1</sup>12 or <sup>2</sup>13, wherein at least one of the norastemizole and the leukotriene inhibitor is administered in an oral solid dosage form.

35. (Amended) The method of claim <sup>3</sup>14, wherein the norastemizole is administered as a nasal or oral spray.

36. (Amended) The method of claim <sup>1</sup>12 or <sup>2</sup>13, wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor.